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who initiated therapy during year 2002 with either an inhaled
corticosteroid or an anticholinergic (ﬁrst ﬁll date identiﬁed as
index date) were included in the analyses. Patients were followed
for one year prior to and one year after the index date. Rate of
switching and augmentation between the two groups was ana-
lyzed descriptively. Multivariate analyses controlling for patient
demographics, comorbidities, baseline health resource utilization
and physician specialty were used to compare costs between the
two groups. RESULTS: Of the 8392 patients identiﬁed as having
COPD, 467 (5.56%) initiated an inhaled corticosteroid and 495
(5.90%) initiated an anticholinergic. Rate of switching (12% 
vs. 10%) and augmentation (32% vs. 24%) was higher in the
inhaled corticosteroid group as compared to the anticholinergic
group. After adjusting for the confounding factors, multivariate
analysis revealed that the initiating inhaled corticosteroid group
had 68% higher respiratory costs and 20% higher overall costs
as compared to the initiating anticholinergic group during the
one-year follow-up period (p < 0.05). CONCLUSIONS: The
inhaled corticosteroid users had higher rates of switching/aug-
mentation and higher respiratory and overall costs as compared
to the anticholinergic users. Future research determining the
reasons for higher follow-up cost in the inhaled corticosteroid
group would be helpful.
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OBJECTIVES: The Canadian Thoracic Society (CTS) guidelines
for the management of Chronic Obstructive Pulmonary Disease
(COPD) recommend incorporating combination therapy [long-
acting B2-agonist (LABA) and an inhaled-corticosteroid (ICS)]
for select COPD patients but have not evaluated the associated
economic implications. Our objective was to provide economic
information to inform decision makers whether to recommend
combination therapy to none, all, or a select group of COPD
patients. METHODS: Using clinical guidelines and current man-
agement of COPD as the basis for the analysis, a markov model
was constructed to determine, from a health systems perspective,
the cost-effectiveness of combination therapy versus LABA alone
between four treatment strategies: 1) maintenance therapy for all
patients using LABA alone (base case); and in addition to the
base case, 2) provide combination therapy for severe cases
(forced expiratory volume in 1 second [FEV1] < 35% predicted);
3) provide combination therapy for moderate or severe cases
(FEV1 < 50% predicted); and 4) provide combination therapy
for all COPD patients. Estimates of mortality, exacerbation and
disease progression rates, and outcomes (QALY) were derived
from a systematic review of the literature. Cost estimates were
based on current Alberta healthcare costs. A time horizon of 3
years was used. RESULTS: Beginning with the lowest cost inter-
vention of LABA for all cases: the incremental cost-effectiveness
ratio (ICER) of providing combination therapy for severe
patients was $9670 per QALY gained. The marginal ICER for
providing combination therapy for moderate and severe cases 
is $31,606 per QALY gained and providing combination therapy
for all stages of disease was $271,241 per QALY gained. 
CONCLUSION: It would be cost-effective to provide combina-
tion therapy for moderate and severe COPD patients. This analy-
sis has signiﬁcant implications for the planned revision of CTS
guidelines because it promotes the wider use of combination
therapy in COPD populations with greater severity.
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OBJECTIVES: COPD is a leading cause of morbidity and mor-
tality in the U.S., and is a major source of healthcare costs. Life-
time costs of COPD and its impact on life expectancy have 
not been adequately quantiﬁed. METHODS: We developed a
Markov model to project mortality and costs from COPD over
an individual’s remaining lifetime. The model proﬁles patients
with diagnosed COPD by sex, age (30, 40, 50, 60, 70, 80 years),
smoking status (current, former, never smoker), and COPD
severity (GOLD stages I–IV). Changes/transitions for these
factors, along with mortality, occur in each one-year model cycle.
Data were obtained from published sources and analyses of gov-
ernment survey and claims databases. The model projects direct
costs (undiscounted and discounted to 2005 US$ at 3% per
annum) and life expectancy (age at death and quality-adjusted
life years [QALYs] remaining). RESULTS: For a “typical” COPD
patient (60 years old, former smoker, GOLD stage I or II), dis-
counted lifetime costs of COPD were projected to range from
$38,000–$74,000 (men) and $43,000–$85,000 (women) for
GOLD stages I and II, respectively. Unadjusted remaining life
expectancy was 19.6/22.0 years (men/women) for GOLD stage
I, and 16.6/19.0 years (men/women) for GOLD stage II.
Men/women in GOLD stages I and II respectively had 1.4/2.3
and 4.4/5.3 fewer years remaining in life compared to average
60-year-olds in the general U.S. population. Quality-adjusted life
expectancy for men/women was 17.0/18.9 and 12.0/13.7 QALYs
for GOLD stages I and II, respectively. CONCLUSION: Lifetime
burden of COPD for individuals with the disease is considerable.
Costs and life-years lost for GOLD stage II patients are about
double to triple for those in GOLD stage I. These results high-
light the potential clinical and economic beneﬁts of slowing
disease progression.
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Little is known about the costs of treating idiopathic pulmonary
ﬁbrosis (IFP), an infrequent but often fatal chronic respiratory
disease. OBJECTIVE: To assess resource use and costs of care
for IPF, pulmonary care, and all healthcare services among newly
diagnosed IPF patients. METHODS: Patients newly diagnosed
with IPF were identiﬁed from the administrative claims records
of a large state Medicaid program. Patients were selected for
inclusion if they had (1) 1+ inpatient claims or 2+ outpatient
claims listing a ICD-9-CM diagnosis of IPF (515, 516.3¥)
between July 1999-June 2003; and (2) fee-for-service, Medicaid-
only coverage for 12+ months before and after their ﬁrst
observed claim with an IPF diagnosis (“index date”). Patients
who died during the 12-month post-index period also were
included. Patients were excluded if they had an IPF diagnosis 
in the 12 months prior to the index date, or diagnoses for 
extrinsic allergic alveolitis, pneumoconioses, lung diseases due to
